Home Newsfeeds Credit Suisse Maintains Outperform on Acuity Brands, Lowers Price Target to $200

Credit Suisse Maintains Outperform on Acuity Brands, Lowers Price Target to $200

Credit Suisse analyst John Walsh maintains Acuity Brands (NYSE:AYI) with a Outperform and lowers the price target from $211 to $200.

byBenzinga Newsdesk

July 1, 2022

1 minute read

Credit Suisse analyst John Walsh maintains Acuity Brands (NYSE:AYI) with a Outperform and lowers the price target from $211 to $200.

Jack Dorsey’s Block Co-Leads $2M Investment In Africa-Based Renewable Bitcoin Miner

By Shivdeep Dhaliwal

December 6, 11:03 PM

Gridless said that it has secured a $2 million seed investment round, led by Stillmark, a Bitcoin (CRYPTO: BTC)-focused venture capital firm and Twitter co-founder Jack Dorse

BTC

S&P 500, Nasdaq Futures Point To Lackluster Start As Friday’s Jobs Report, Pre-Holiday Mood Keeps Sentiment Subdued

By Shanthi Rexaline

September 2, 7:16 AM

The major U.S. index futures point to a nervous start on Friday, as investors choose to exercise restraint ahead of the non-farm payrolls report for August.

AVGO

NVE Q2 EPS $1.26 Up From $0.75 YoY, Sales $10.72M Up From $6.82M YoY

By Michael Horton

October 19, 5:10 PM

NVE (NASDAQ:NVEC) reported quarterly earnings of $1.26 per share. This is a 68 percent increase over earnings of $0.75 per share from the same period last year. The company reported $10.72 million in sales this quarter.

NVEC

EMA Talks Ongoing With Moderna About Application For Spikevax BA.4/BA.5 Adapted Bivalent Covid-19 Vaccine, Start Of Review Expected End Of Sept

By Benzinga Newsdesk

September 20, 9:42 AM

- Reuters

MRNA

Credit Suisse Maintains Outperform on Acuity Brands, Lowers Price Target to $200

Related Posts

Jack Dorsey’s Block Co-Leads $2M Investment In Africa-Based Renewable Bitcoin Miner

S&P 500, Nasdaq Futures Point To Lackluster Start As Friday’s Jobs Report, Pre-Holiday Mood Keeps Sentiment Subdued

NVE Q2 EPS $1.26 Up From $0.75 YoY, Sales $10.72M Up From $6.82M YoY

EMA Talks Ongoing With Moderna About Application For Spikevax BA.4/BA.5 Adapted Bivalent Covid-19 Vaccine, Start Of Review Expected End Of Sept